Collectively, and combined with our findings, showing increased paclitaxel resistance in these gene KOs (Fig. 2), our results define ATP8B3, FOXR2, FRG2 and HIST1H4A as cancer stemness negative regulators, consistent with a role for these genes as potential drug (paclitaxel) sensitizers (Fig. 2). Here, FOXR2 is linked to cancer.